JP7591155B2 - 置換ピリドトリアジン化合物及びその使用 - Google Patents

置換ピリドトリアジン化合物及びその使用 Download PDF

Info

Publication number
JP7591155B2
JP7591155B2 JP2023543136A JP2023543136A JP7591155B2 JP 7591155 B2 JP7591155 B2 JP 7591155B2 JP 2023543136 A JP2023543136 A JP 2023543136A JP 2023543136 A JP2023543136 A JP 2023543136A JP 7591155 B2 JP7591155 B2 JP 7591155B2
Authority
JP
Japan
Prior art keywords
pharma
acceptable salt
compound
ceutically acceptable
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023543136A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024503116A (ja
Inventor
ハン チュー,
ブエンロストロ, アナ ゼット. ゴンザレス
ホンヤン グオ,
シャオチュン ハン,
アンナ イー. ハートレー,
ラン ジアン,
ジャヤオ リー,
デイビッド ダブリュー. リン,
マイケル エル. ミッチェル,
デヴァン ナドゥサンビ,
グレッグ エム. シュワルツワルダー,
スザンヌ エム. シェフチェク,
バーゲン, マシュー ジェイ. フォン
チャオイン ウー,
ホン ヤン,
ジェニファー アール. ジャン,
Original Assignee
ギリアード サイエンシーズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ギリアード サイエンシーズ, インコーポレイテッド filed Critical ギリアード サイエンシーズ, インコーポレイテッド
Publication of JP2024503116A publication Critical patent/JP2024503116A/ja
Priority to JP2024165518A priority Critical patent/JP7759459B2/ja
Application granted granted Critical
Publication of JP7591155B2 publication Critical patent/JP7591155B2/ja
Priority to JP2025030163A priority patent/JP2025087755A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023543136A 2021-01-19 2022-01-18 置換ピリドトリアジン化合物及びその使用 Active JP7591155B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024165518A JP7759459B2 (ja) 2021-01-19 2024-09-24 置換ピリドトリアジン化合物及びその使用
JP2025030163A JP2025087755A (ja) 2021-01-19 2025-02-27 置換ピリドトリアジン化合物及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163139237P 2021-01-19 2021-01-19
US63/139,237 2021-01-19
US202163190461P 2021-05-19 2021-05-19
US63/190,461 2021-05-19
PCT/US2022/012773 WO2022159387A1 (en) 2021-01-19 2022-01-18 Substituted pyridotriazine compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024165518A Division JP7759459B2 (ja) 2021-01-19 2024-09-24 置換ピリドトリアジン化合物及びその使用

Publications (2)

Publication Number Publication Date
JP2024503116A JP2024503116A (ja) 2024-01-24
JP7591155B2 true JP7591155B2 (ja) 2024-11-27

Family

ID=80514578

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2023543136A Active JP7591155B2 (ja) 2021-01-19 2022-01-18 置換ピリドトリアジン化合物及びその使用
JP2024165518A Active JP7759459B2 (ja) 2021-01-19 2024-09-24 置換ピリドトリアジン化合物及びその使用
JP2025030163A Withdrawn JP2025087755A (ja) 2021-01-19 2025-02-27 置換ピリドトリアジン化合物及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024165518A Active JP7759459B2 (ja) 2021-01-19 2024-09-24 置換ピリドトリアジン化合物及びその使用
JP2025030163A Withdrawn JP2025087755A (ja) 2021-01-19 2025-02-27 置換ピリドトリアジン化合物及びその使用

Country Status (26)

Country Link
US (4) US11613546B2 (cg-RX-API-DMAC7.html)
EP (2) EP4321217A3 (cg-RX-API-DMAC7.html)
JP (3) JP7591155B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230134529A (cg-RX-API-DMAC7.html)
AU (2) AU2022210247C1 (cg-RX-API-DMAC7.html)
CA (1) CA3202957A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023002074A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023009518A2 (cg-RX-API-DMAC7.html)
CR (2) CR20260070A (cg-RX-API-DMAC7.html)
DK (1) DK4196479T5 (cg-RX-API-DMAC7.html)
DO (1) DOP2023000139A (cg-RX-API-DMAC7.html)
ES (1) ES2968058T3 (cg-RX-API-DMAC7.html)
FI (1) FI4196479T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20231654T2 (cg-RX-API-DMAC7.html)
HU (1) HUE064467T2 (cg-RX-API-DMAC7.html)
IL (1) IL304222A (cg-RX-API-DMAC7.html)
LT (1) LT4196479T (cg-RX-API-DMAC7.html)
MX (1) MX2023008137A (cg-RX-API-DMAC7.html)
PE (2) PE20231297A1 (cg-RX-API-DMAC7.html)
PL (1) PL4196479T3 (cg-RX-API-DMAC7.html)
PT (1) PT4196479T (cg-RX-API-DMAC7.html)
SA (1) SA523441639B1 (cg-RX-API-DMAC7.html)
SI (1) SI4196479T1 (cg-RX-API-DMAC7.html)
TW (2) TW202408533A (cg-RX-API-DMAC7.html)
WO (1) WO2022159387A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202306360B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024173998A (ja) * 2021-01-19 2024-12-13 ギリアード サイエンシーズ, インコーポレイテッド 置換ピリドトリアジン化合物及びその使用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240151256A (ko) 2019-03-22 2024-10-17 길리애드 사이언시즈, 인코포레이티드 가교된 트리시클릭 카르바모일피리돈 화합물 및 그의 제약 용도
EP4110783A1 (en) 2020-02-24 2023-01-04 Gilead Sciences, Inc. Tetracyclic compounds for treating hiv infection
CN116390924B (zh) 2020-09-30 2025-11-07 吉利德科学公司 桥连三环氨基甲酰基吡啶酮化合物及其用途
US20250230161A1 (en) * 2021-08-11 2025-07-17 Merck Sharp & Dohme Llc Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenza
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2025184452A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025184448A2 (en) * 2024-03-01 2025-09-04 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds
WO2025184447A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
WO2026020086A1 (en) 2024-07-19 2026-01-22 Gilead Sciences, Inc. Methods and pharmaceutical formulations for treating viral infections

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019160783A1 (en) 2018-02-15 2019-08-22 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as hiv integrase inhibitors
WO2019230858A1 (ja) 2018-05-31 2019-12-05 塩野義製薬株式会社 多環性カルバモイルピリドン誘導体
WO2019236396A1 (en) 2018-06-05 2019-12-12 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as hiv integrase inhibitors
WO2020075080A1 (en) 2018-10-10 2020-04-16 Janssen Biopharma, Inc. Macrocyclic flu endonuclease inhibitors
WO2020197991A1 (en) 2019-03-22 2020-10-01 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
WO2021007506A1 (en) 2019-07-11 2021-01-14 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Compounds useful to treat influenza virus infections

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
SG182849A1 (en) 2003-04-25 2012-08-30 Gilead Sciences Inc Antiviral phosphonate analogs
PT2258376T (pt) 2004-07-27 2019-05-31 Gilead Sciences Inc Análogos fosfonatados de compostos inibidores do vih
WO2006088173A1 (ja) 2005-02-21 2006-08-24 Shionogi & Co., Ltd. Hivインテグラーゼ阻害活性を有する2環性カルバモイルピリドン誘導体
WO2006103399A1 (en) 2005-03-31 2006-10-05 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hiv integrase inhibitors
DK3187225T3 (da) 2005-04-28 2022-02-28 Viiv Healthcare Co Polycyklisk carbamoylpyridonderivat med hiv-integrasehæmmende aktivitet
JP2006342115A (ja) 2005-06-10 2006-12-21 Shionogi & Co Ltd Hivインテグラーゼ阻害活性を有する多環性化合物
US20080214527A1 (en) 2005-08-04 2008-09-04 Takashi Kawasuji Hiv Integrase Inhibitors
TW200800988A (en) 2005-10-27 2008-01-01 Shionogi & Amp Co Ltd Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
AU2006306355A1 (en) 2005-10-27 2007-05-03 Merck & Co., Inc. HIV integrase inhibitors
TW200811153A (en) 2006-06-23 2008-03-01 Japan Tobacco Inc 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor
WO2008010964A1 (en) 2006-07-17 2008-01-24 Merck & Co., Inc. 1-hydroxy naphthyridine compounds as anti-hiv agents
CA2665538A1 (en) 2006-10-18 2008-04-24 Merck & Co., Inc. Hiv integrase inhibitors
US8354429B2 (en) 2007-11-16 2013-01-15 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
EP2231621B1 (en) 2008-01-08 2016-11-02 Merck Sharp & Dohme Corp. Process for preparing n-substituted hydroxypyrimidinone carboxamides
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
TWI443098B (zh) 2008-03-24 2014-07-01 Medivation Technologies Inc 吡啶并〔3,4-b〕吲哚及使用方法
WO2009154870A1 (en) 2008-05-05 2009-12-23 Merck & Co., Inc. Hiv integrase inhibitors
EP2247601B1 (en) 2008-07-02 2013-04-10 Avexa Limited Thiazopyrimidinones and uses thereof
WO2010011812A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
ES2395705T3 (es) 2008-07-25 2013-02-14 Glaxosmithkline Llc Compuestos químicos
WO2010011819A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011815A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011818A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
EP2660239B1 (en) 2008-07-25 2016-11-23 VIIV Healthcare Company Chemical compounds as synthetic intermediates
EP2349276B1 (en) 2008-10-06 2019-11-27 Merck Sharp & Dohme Corp. Hiv integrase inhibitors
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
SG171308A1 (en) 2008-12-11 2011-07-28 Shionogi & Co Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
JP2012516333A (ja) 2009-01-28 2012-07-19 メルク・シャープ・エンド・ドーム・コーポレイション Hivインテグラーゼ阻害剤としての架橋化合物
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
JP5737691B2 (ja) 2009-06-15 2015-06-17 塩野義製薬株式会社 置換された多環性カルバモイルピリドン誘導体
WO2011011483A1 (en) 2009-07-22 2011-01-27 Glaxosmithkline Llc Chemical compounds
EP2470014A4 (en) 2009-08-26 2013-01-16 Merck Sharp & Dohme HIV integrase inhibitors
WO2011045330A1 (en) 2009-10-13 2011-04-21 Tibotec Pharmaceuticals Macrocyclic integrase inhibitors
EP3351249A1 (en) 2010-01-27 2018-07-25 VIIV Healthcare Company Antiviral therapy
CN102858771A (zh) 2010-02-26 2013-01-02 日本烟草产业株式会社 1,3,4,8-四氢-2H-吡啶并[1,2-a]吡嗪衍生物及其作为HIV整合酶抑制剂的用途
WO2011121105A1 (en) 2010-04-02 2011-10-06 Tibotec Pharmaceuticals Macrocyclic integrase inhibitors
WO2011129095A1 (ja) 2010-04-12 2011-10-20 塩野義製薬株式会社 インテグラーゼ阻害活性を有するピリドン誘導体
WO2011139637A1 (en) 2010-05-03 2011-11-10 Philadelphia Health & Education Corporation Small-molecule modulators of hiv-1 capsid stability and methods thereof
CN103140474A (zh) 2010-07-02 2013-06-05 吉里德科学公司 治疗aids的萘-2-基乙酸衍生物
EP2588455B1 (en) 2010-07-02 2018-04-04 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
SMT202100268T1 (it) 2010-08-05 2021-07-12 Shionogi & Co Metodo per produrre composti aventi attività di inibizione di integrasi di hiv.
TWI577377B (zh) 2010-09-16 2017-04-11 Viiv醫療保健公司 醫藥組合物
AU2011320651A1 (en) 2010-10-29 2013-05-02 Merck Canada Inc. HIV integrase inhibitors
US8835411B2 (en) 2010-12-10 2014-09-16 Bristol-Myers Squibb Company HIV integrase inhibitors
MX2013012266A (es) 2011-04-21 2013-11-22 Gilead Sciences Inc Compuestos de benzotiazol y su uso farmaceutico.
CA2840095A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
AU2012321762A1 (en) 2011-10-12 2014-04-17 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase-inhibiting activity
JP6144698B2 (ja) 2011-12-20 2017-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Hiv複製の阻害剤としての縮合三環式化合物
ES2571479T3 (es) 2012-04-20 2016-05-25 Gilead Sciences Inc Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH
JP2015527855A (ja) 2012-06-25 2015-09-17 サンパワー コーポレイション 太陽電池アレイ
WO2014008636A1 (en) 2012-07-11 2014-01-16 Merck Sharp & Dohme Corp. Macrocyclic compounds as hiv integrase inhibitors
US20150166520A1 (en) 2012-07-20 2015-06-18 Merck Sharp & Dohme Corp. Amido-substituted pyrimidinone derivatives useful for the treatment of hiv infection
US8906929B2 (en) 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
DE102012220513B4 (de) 2012-11-12 2023-02-16 Bayerische Motoren Werke Aktiengesellschaft Verfahren und Vorrichtung zur Herstellung eines Druckgussteils
EP2931730B1 (en) 2012-12-17 2019-08-07 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
HK1214817A1 (en) 2012-12-27 2016-08-05 Japan Tobacco Inc. Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as hiv integrase inhibitor
US9493479B2 (en) 2013-04-16 2016-11-15 Merck Sharp & Dohme Corp. Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors
SI2997033T1 (en) 2013-05-17 2018-04-30 Merck Sharp & Dohme Corp. FUZYCLE TRICYCLE HETEROCYCLIC COMPOUNDS AS HIV INTEGRATED INHIBITORS
US9951079B2 (en) 2013-06-13 2018-04-24 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
DK3019503T3 (da) 2013-07-12 2017-11-20 Gilead Sciences Inc Polycykliske-carbamoylpyridon-forbindelser og anvendelse deraf til behandling af hiv-infektioner
NO2865735T3 (cg-RX-API-DMAC7.html) 2013-07-12 2018-07-21
WO2015039348A1 (en) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
CA2924829C (en) 2013-09-27 2019-10-29 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
WO2015089847A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
NO2717902T3 (cg-RX-API-DMAC7.html) 2014-06-20 2018-06-23
WO2016027879A1 (ja) 2014-08-22 2016-02-25 塩野義製薬株式会社 インテグラーゼ阻害活性を有する多環性ピリドン誘導体
WO2016033009A1 (en) 2014-08-27 2016-03-03 Bristol-Myers Squibb Company Imidazo[1,2-a]pyridine derivatives for use as inhibitors of human immunodeficiency virus replication
WO2016090545A1 (en) 2014-12-09 2016-06-16 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrate inhibitors
WO2016094198A1 (en) 2014-12-09 2016-06-16 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
US10081647B2 (en) 2015-03-26 2018-09-25 Merck Sharp & Dohme Corp. Phosphate substituted quinolizine derivatives useful as HIV integrase inhibitors
CA2980362C (en) 2015-04-02 2020-02-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
US10624912B2 (en) 2015-11-17 2020-04-21 Merck Sharp & Dohme Corp. Spirocyclic Pyridotriazine Derivatives useful as HIV integrase inhibitors
US10548910B2 (en) 2015-11-17 2020-02-04 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors
EP3389380B1 (en) 2015-12-15 2021-07-21 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
WO2017113288A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
JP7160466B2 (ja) 2016-06-23 2022-10-25 ヴィーブ ヘルスケア カンパニー 治療薬の送達のための組成物及び方法
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
WO2018102634A1 (en) 2016-12-02 2018-06-07 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as hiv integrase inhibitors
WO2018109786A1 (en) 2016-12-16 2018-06-21 Cipla Limited Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
WO2018140368A1 (en) 2017-01-26 2018-08-02 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
CN111970949A (zh) 2018-02-13 2020-11-20 冷蒸汽解决方案公司 用于对气流进行加湿和冷却的方法及组合物
WO2019209667A1 (en) 2018-04-27 2019-10-31 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as hiv integrase inhibitors
CN110526930B (zh) 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
EP3805221A4 (en) 2018-05-31 2022-01-05 Shionogi & Co., Ltd POLYCYCLIC PYRIDONE DERIVATIVE
JP7394074B2 (ja) 2018-05-31 2023-12-07 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 治療用化合物
WO2019244066A2 (en) 2018-06-19 2019-12-26 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2020003093A1 (en) 2018-06-25 2020-01-02 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
EP3815689A4 (en) 2018-06-27 2022-04-20 National University Corporation Hokkaido University ARENAVIRUS GROWTH INHIBITOR WITH POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE
EP4751717A3 (en) 2018-10-22 2026-08-05 Board of Regents of the University of Nebraska Antiviral prodrugs and nanoformulations thereof
CN118873676A (zh) 2018-11-29 2024-11-01 内布拉斯加大学董事会 抗病毒前药及其纳米制剂
WO2020221294A1 (zh) 2019-04-30 2020-11-05 上海拓界生物医药科技有限公司 桥环-3,4-二氢-吡啶并[1,2-a]吡嗪-1,8-二酮化合物及其药物用途
RU2717101C1 (ru) 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
TW202120510A (zh) 2019-11-13 2021-06-01 大陸商上海拓界生物醫藥科技有限公司 新型四環雜環化合物及其藥物用途
WO2021107065A1 (ja) 2019-11-28 2021-06-03 塩野義製薬株式会社 多環性ピリドピラジン誘導体
US12564595B2 (en) 2019-11-28 2026-03-03 Shionogi & Co., Ltd. Prophylactic and therapeutic pharmaceutical agent for HIV infectious diseases characterized by comprising combination of integrase inhibitor and anti-HIV agent
EP4110783A1 (en) 2020-02-24 2023-01-04 Gilead Sciences, Inc. Tetracyclic compounds for treating hiv infection
CN116390924B (zh) 2020-09-30 2025-11-07 吉利德科学公司 桥连三环氨基甲酰基吡啶酮化合物及其用途
TW202227445A (zh) 2020-10-30 2022-07-16 大陸商上海拓界生物醫藥科技有限公司 抑制基因缺陷的hiv病毒的用途
CR20260070A (es) 2021-01-19 2026-04-24 Gilead Sciences Inc COMPUESTOS DE PIRIDOTRIAZINA SUSTITUIDOS Y USOS DE ESTOS (Divisional 2023-0315)
US11958864B2 (en) 2021-02-16 2024-04-16 Merck Sharp & Dohme Llc Tetracyclic heterocycle compounds useful as HIV integrase inhibitors
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019160783A1 (en) 2018-02-15 2019-08-22 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as hiv integrase inhibitors
WO2019230858A1 (ja) 2018-05-31 2019-12-05 塩野義製薬株式会社 多環性カルバモイルピリドン誘導体
WO2019236396A1 (en) 2018-06-05 2019-12-12 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as hiv integrase inhibitors
WO2020075080A1 (en) 2018-10-10 2020-04-16 Janssen Biopharma, Inc. Macrocyclic flu endonuclease inhibitors
WO2020197991A1 (en) 2019-03-22 2020-10-01 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
WO2021007506A1 (en) 2019-07-11 2021-01-14 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Compounds useful to treat influenza virus infections

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024173998A (ja) * 2021-01-19 2024-12-13 ギリアード サイエンシーズ, インコーポレイテッド 置換ピリドトリアジン化合物及びその使用
JP7759459B2 (ja) 2021-01-19 2025-10-23 ギリアード サイエンシーズ, インコーポレイテッド 置換ピリドトリアジン化合物及びその使用

Also Published As

Publication number Publication date
PT4196479T (pt) 2024-01-03
DK4196479T3 (da) 2024-01-22
US12187734B2 (en) 2025-01-07
SI4196479T1 (sl) 2024-01-31
IL304222A (en) 2023-09-01
FI4196479T3 (fi) 2024-01-17
EP4321217A3 (en) 2024-04-10
EP4196479B1 (en) 2023-11-01
AU2022210247B2 (en) 2024-07-18
HUE064467T2 (hu) 2024-03-28
EP4321217A2 (en) 2024-02-14
US11613546B2 (en) 2023-03-28
ZA202306360B (en) 2024-04-24
CO2023009518A2 (es) 2023-07-21
DOP2023000139A (es) 2023-08-15
KR20230134529A (ko) 2023-09-21
CA3202957A1 (en) 2022-07-28
TW202237128A (zh) 2022-10-01
US11897892B2 (en) 2024-02-13
CR20260070A (es) 2026-04-24
AU2022210247C1 (en) 2026-06-18
AU2022210247A9 (en) 2024-05-09
ES2968058T3 (es) 2024-05-07
US20220267343A1 (en) 2022-08-25
WO2022159387A1 (en) 2022-07-28
US20240300966A1 (en) 2024-09-12
AU2022210247A1 (en) 2023-08-17
AU2024223997A1 (en) 2024-10-24
PE20231297A1 (es) 2023-08-22
MX2023008137A (es) 2023-07-21
CL2023002074A1 (es) 2024-01-12
EP4196479B9 (en) 2024-10-16
CL2024001793A1 (es) 2024-11-15
JP7759459B2 (ja) 2025-10-23
US20250188089A1 (en) 2025-06-12
TW202408533A (zh) 2024-03-01
DK4196479T5 (da) 2025-01-02
HRP20231654T2 (hr) 2025-01-03
JP2024503116A (ja) 2024-01-24
TWI824384B (zh) 2023-12-01
PE20242099A1 (es) 2024-10-28
JP2024173998A (ja) 2024-12-13
US20230257389A1 (en) 2023-08-17
EP4196479A1 (en) 2023-06-21
PL4196479T3 (pl) 2024-03-18
HRP20231654T1 (hr) 2024-03-15
JP2025087755A (ja) 2025-06-10
SA523441639B1 (ar) 2024-07-31
CR20230315A (es) 2023-09-01
LT4196479T (lt) 2023-12-11

Similar Documents

Publication Publication Date Title
JP7759459B2 (ja) 置換ピリドトリアジン化合物及びその使用
KR102934440B1 (ko) 가교된 트리사이클릭 카르바모일피리돈 화합물 및 이의 용도
US12122776B2 (en) Tetracyclic compounds and uses thereof
KR102240584B1 (ko) 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
CN116745292A (zh) 经取代的吡啶并三嗪化合物及其用途
HK40104840A (en) Substituted pyridotriazine compounds and uses thereof
HK40094146B (en) Substituted pyridotriazine compounds and uses thereof
HK40094146A (en) Substituted pyridotriazine compounds and uses thereof
EA051450B1 (ru) Замещенные соединения пиридотриазина и их применение
KR20250093585A (ko) Hiv 감염을 치료하기 위한 사환식 화합물
EA051994B1 (ru) Тетрациклические соединения для лечения вич-инфекции

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230727

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230727

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240624

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240924

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241115

R150 Certificate of patent or registration of utility model

Ref document number: 7591155

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150